Eli Lilly’s Kisunla Receives FDA Approval for Dosing Change
The U.S. Food and Drug Administration (FDA) has officially approved an updated dosing schedule for Eli Lilly and Co.’s Kisunla (donanemab-azbt). This innovative therapy is aimed at treating adults experiencing the early symptoms of Alzheimer’s disease (AD).
The New Dosing Regimen Explained
The updated treatment plan features a new titration dosing schedule intended to enhance the administration of Kisunla, which is recognized as an amyloid-targeting therapy. This change allows for a more gradual titration compared to the previous recommendations.
Benefits of the Adjusted Schedule
The new recommendation significantly minimizes the risk of amyloid-related imaging abnormalities with edema/effusion (ARIA-E), which are potential side effects ofamyloid plaque-targeting treatments. While ARIA-E is often asymptomatic, some cases can lead to serious complications.
Insights from the TRAILBLAZER-ALZ 6 Study
Research findings from the TRAILBLAZER-ALZ 6 study underscore the efficacy of the modified dosing schedule. The study revealed that patients receiving the new regimen experienced a notable decrease in ARIA-E incidents, dropping from 24% to just 14% compared to the original plan, indicating a relative risk reduction of 41%. Furthermore, at the 52-week mark, rates of ARIA-E were reduced from 25% to 16% in the new dosing group.
Understanding ARIA Variants
ARIA stands for amyloid-related imaging abnormalities, which can manifest in two forms: ARIA-E, characterized by edema, and ARIA-H, marked by hemosiderin deposits. These abnormalities were reported in 29% of participants at week 52, demonstrating the importance of careful monitoring during treatment.
Comparative Efficacy of Dosing Regimens
Patients who followed the modified titration experienced similar levels of amyloid plaque reduction compared to those on the original schedule. After 24 weeks, average amyloid plaque levels had decreased by 67% in the modified group, compared to 69% for those on the original dosing regimen.
No New Adverse Reactions Reported
In this study, no new adverse reactions were identified. However, incidences of hypersensitivity and infusion-related reactions were reported at higher frequencies, suggesting that patients should remain vigilant during treatment.
Future Regulatory Considerations
Earlier this year, the European Medicines Agency (EMA) expressed reservations regarding the marketing authorization for Kisunla in early symptomatic Alzheimer’s patients. Eli Lilly plans to pursue a re-examination of this decision, aiming for broader acceptance of their innovative treatment.
Current Stock Performance
As for Eli Lilly’s stock performance, the shares of LLY are seeing modest growth, with a slight increase recorded recently. This reflects ongoing investor confidence in the company's developments within the Alzheimer's treatment landscape.
Frequently Asked Questions
What is Kisunla used for?
Kisunla is an amyloid-targeting therapy approved for treatment in adults showing early symptomatic Alzheimer's disease.
How does the new dosing schedule differ from the previous one?
The new schedule allows for a more gradual administration of the drug, potentially reducing side effects.
What were the results of the TRAILBLAZER-ALZ 6 study?
The study demonstrated a significant reduction in ARIA-E incidents among patients receiving the new dosing regimen compared to the original plan.
Are there any new adverse effects reported with the updated regimen?
No new adverse reactions have been reported, but there were higher instances of hypersensitivity and infusion-related reactions.
What are investors saying about Eli Lilly's stock?
Investors show optimism towards Eli Lilly’s stock as the company continues to innovate in Alzheimer's treatment and work on regulatory approval.
